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Very low-density lipoprotein-apoprotein CI is increased in dia- It is well known that there is a high incidence of coro-
betic nephropathy: Comparison with apoprotein CIII. nary heart disease (CHD) in patients with chronic renal
Background. Recent studies have suggested that apoprotein failure (CRF) due to diabetic nephropathy, which results(apo) CI in very low-density lipoprotein (VLDL) plays an impor-
in a significantly higher morbidity and mortality rate thantant role in causing hypertriglyceridemia independent of apo
in their nondiabetic counterparts [1–3]. A recent prospec-CIII, which is associated with coronary heart disease (CHD).
Because the incidence of CHD is increased in diabetic patients tive cohort study of patients with type 2 diabetes mellitus
and is even higher when diabetic nephropathy is developed, has demonstrated that diabetic nephropathy is signifi-
we measured apo CI levels in VLDL from type 2 diabetic cantly associated with subsequent mortality from CHDpatients, with various degree of nephropathy, and compared
even before end-stage renal disease (ESRD) occurs [4].the results with those for healthy controls or nondiabetic pa-
The pathogenesis of CHD in diabetic nephropathy istients with chronic renal failure (CRF).
Methods. This study enrolled healthy control subjects, type multifactorial, but dyslipidemia is thought to be a strong
2 diabetic patients with normoalbuminuria, microalbuminuria, risk factor for coronary atherosclerosis [3–8]. Several
overt proteinuria, and CRF on hemodialysis and nondiabetic
studies, including ours, suggested that an atherogenic lipo-hemodialyis patients. VLDL (density 1.006) was separated
protein profile, such as an increase of very low-densityby ultracentrifugation. Then the apo CI, CIII, and B concentra-
tions in VLDL were measured by enzyme-linked immunosor- lipoprotein (VLDL) and intermediate-density lipopro-
bent assay (ELISA). tein (IDL) along with decrease of high-density lipopro-
Results. The apo CI, CIII, and B concentrations in VLDL tein (HDL)-cholesterol and LDL size, becomes more
were respectively 3-, 2-, and 2-fold higher, respectively, in dia-
prominent in type 2 diabetic patients who have diabeticbetic patients with overt proteinuria than in controls. Hemodi-
nephropathy [5–10]. Although lipid metabolism has beenalysis patients with diabetic nephropathy had levels of apo CI,
CIII, and B in VLDL that were 2.6-, 2.7- and 2-fold higher, extensively investigated in diabetes, little information is
respectively, than those in controls. Nondiabetic hemodialysis available concerning the influence of nephropathy on
patients also had a 2.7-fold higher level of VLDL apo CIII, diabetic dyslipidemia. It remains unclear how lipoproteinwhereas VLDL apo CI and VLDL apo B were not significantly
abnormalities worsen with increasing severity of diabeticincreased. VLDL apo CI was significantly correlated with VLDL
nephropathy, and whether lipoprotein changes are at-apo B independently of VLDL apo CIII level.
Conclusion. An increase of VLDL apo CIII is a prominent tributable to diabetes-related metabolic abnormalities
feature of dyslipidemia in CRF patients, regardless of whether or renal dysfunction.
they are diabetic or nondiabetic, whereas an increase of VLDL We recently reported that the number of VLDL parti-apo CI is more specific to diabetic nephropathy and is closely
cles [as estimated from the apoprotein (apo) B concen-associated with an increase of VLDL particle numbers, a new
risk factor for CHD. tration in VLDL] was markedly increased in Japanese
men with CHD, and that this was a superior discrimina-
tor for CHD/non-CHD when compared with established
coronary risk factors such as LDL-cholesterol level or
LDL size [11]. That preliminary report also showed that
the apo CI level in VLDL was markedly increased inKey words: apoprotein CI, apoprotein CIII, VLDL, diabetic nephropa-
thy, chronic renal failure. CHD and was associated with CHD events indepen-
dently of apo CIII [11]. Apo CI was shown to inhibitReceived for publication August 24, 2002
VLDL particle removal by the liver as did apo CIII inand in revised form November 18, 2002
Accepted for publication January 28, 2003 a liver perfusion study performed using rats [12]. Recent
studies have indicated that human apo C1 transgenic 2003 by the International Society of Nephrology
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Table 1. General and metabolic characteristics of subjects
Type 2 diabetes
Nondiabetic Nondiabetic
control Normo Micro Overt Hemodialysis hemodialysis
Number M/F 42 (24/18) 40 (21/19) 15 (8/7) 17 (10/7) 17 (10/7) 29 (18/11)
Age years 592 622 643 652 603 603
BMI kg/m2 23.70.6 23.60.7 24.41.0 24.90.8 22.61.0 20.20.5a,b,c,d
Therapy mode for diabetes (DI:OHA:INS) 4:31:5 0:12:3 0:13:4 7:5:5
Albumin/creatinine index mg/g 143 171 10919a,b 2312478a,b,c NA NA
FPG mg/100 mL 9922 1445a,f 16613a,f 18427a,b,e,f 1317a,f 9531
HbA1c % 5.40.1 7.70.2a,e 8.30.4a,e 7.90.5a,e 5.90.4 NA
Albumin g/100 mL 4.20.1 4.10.0 4.20.0 3.70.2a 3.80.1a 3.90.2
Creatinine mg/100 mL 0.90.0 0.70.0 0.70.0 1.40.3a,b,c 9.50.5a,b,c,d 10.80.3a,b,c,d
Data represent meanSEM. Abbreviations are: normo. normoalbuminuric diabetes; overt, overt proteinuric diabetes; micro, microalbuminuric diabetes; NA, not
available; DI, diet; OHA, oral hypoglycemic agents; ISN, insulin; BMI, body mass index; HbA1c, hemoglobin A1c.
Significance (P  0.0033) was determined by ANOVA. avs. control; bvs. normo; cvs. micro; dvs. overt; evs. diabetic hemodialysis; fvs. nondiabetic hemodialysis
mice are hypertriglyceridemic because of a defect in the albuminuria: normoalbuminuria, albumin/creatinine in-
dex in the urine less than 30 mg/g; microalbuminuria,catabolism of VLDL [13]. In addition, mice with over-
expression of human apo CI and a lack of the LDL re- albumin/ceatinine index in the urine of 30 to 300 mg/g;
and overt diabetic nephropathy, albumin/creatinine in-ceptor develop severe hypertriglyceridemia [14], suggest-
ing that apo CI impairs the catabolism of VLDL via dex in the urine greater than 300 mg/g as described pre-
viously [16]. Diabetic patients with nephropathy hadLDL receptor-independent pathways. However, the role
of apo CI in lipoprotein metabolism remains unknown overt proteinuria but did not have clinical or laboratory
evidence of kidney disease other than diabetic glomerulo-in humans. Because some clinical studies have demon-
strated that the apo B concentration of VLDL is substan- sclerosis. All of the diabetic patients with overt diabetic
nephropathy had long duration of diabetes (more thantially increased in diabetic nephropathy [5, 15], we specu-
lated that VLDL apo CI levels would also be increased, 10 years) and all of these patients also had diabetic reti-
nopathy (Table 1). All diabetic patients were fed an iso-leading to delayed clearance of VLDL and its accumula-
tion in the plasma. This study was carried out to examine caloric diet (26 to 27 Kcal/kg ideal body weight) con-
sisting of 17% protein, 23% fat, and 60% carbohydrate,the apo CI and apo CIII levels in VLDL from diabetic
patients with various stages of nephropathy and nondia- regardless of the presence of nephropathy. Drugs affect-
ing plasma lipid level were discontinued at least 1 monthbetic patients with CRF in order to determine whether
apo CI was independent of apo CIII. prior to blood examination. Most of the diabetic patients
with normoalbuminuria, microalbuminuria, and overt pro-
teinuria were being treated with sulfonylureas (gliben-
METHODS clamide 1.25-5.0 mg/day or gliclazide 20-80 mg/day) and/or
Subjects alpha-glucosidase inhibitors (150 to 300 mg/day acarbose
or 0.6 to 0.9 mg/day voglibose). Five normoalbuminuric,We studied 42 healthy control subjects, 72 type 2 dia-
three microalbuminuric, four proteinuric, and five dia-betic patients with various degrees of albuminuria, and
46 CRF patients on hemodialysis due to diabetic nephrop- betic hemodialysis patients were on insulin therapy. Four
diabetic patients with normoalbuminuria and seven dia-athy (N  17) or nondiabetic kidney disease (N  29).
All of the diabetic patients fulfilled the World Health betic hemodialysis patients were being treated with diet
and exercise therapy only (Table 1). The nondiabetic CRFOrganization (WHO) criteria (1986) for type 2 diabetes
mellitus: their fasting plasma glucose levels were higher patients on hemodialysis consisted of 16 patients with
chronic nephritis, three with immunoglobulin A (Ig A)than 140 mg/dL and/or the plasma glucose level exceeded
200 mg/dL at 2 hours in the 75 g oral glucose tolerance nephritis, three with focal glomerulosclerosis, two with
polycystic kidney, and five with disease of unknown etiol-test. Spot urine samples were collected on at least three
different days and the average albumin/creatinine index ogy. Blood samples were obtained after an overnight
fast. In the patients on hemodialysis, blood samples werein the urine was calculated. Urine specimens contaminated
with bacteria, white blood cells, or red blood cells were obtained immediately before starting dialysis. Total cho-
lesterol, triglyceride, HDL cholesterol, glucose, hemo-excluded. The urinary albumin concentration was mea-
sured by the latex turbidimetric immunoassay method globin A1c, albumin, and creatinine were measured by
standard laboratory procedures. The LDL cholesterolusing a commercially available kit (LA-system; AIC Co.,
Tokyo, Japan) and the diabetic patients were classified level was measured by a direct assay using a commerially
available kit (Choletest LDL, Daiichi Pure Chemical Co.,into the following subgroups according to the level of
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Table 2. Plasma lipid and apoprotein profile of subjects
Type 2 diabetes
Nondiabetic Nondiabetic
control Normo Micro Overt Hemodialysis hemodialysis
Number 42 40 15 17 17 29
Triglyceride mg/100 mL 935 1089 12815 19926a,b,c,f 14612a 1029
Total cholesterol mg/100 mL 1855 2075 2089 23311a 1607b,c,d 1677a,b,c,d
LDL cholesterol mg/100 mL 1134 1325a 1305 1399a 957b,c,d 1005b,c,d
HDL cholesterol mg/100 mL 563 462a 453 473 362a 473
Apoprotein A1 mg/100 mL 1304 1253 1217 1286 1025a,b,c,d,f 1206
Apoprotein B mg/100 mL 762 953a 975a 1087a,e,f 837 815
Apoprotein CII mg/100 mL 3.60.3 4.50.2 5.00.5 7.51.4a,b,f 6.80.7a,b,f 4.00.4
Apoprotein CIII mg/100 mL 9.90.8 9.00.4 10.21.1 15.62.0a,b,c 14.51.4a,b 12.90.9a,b
Apoprotein E mg/100 mL 4.00.1 4.60.1a 4.80.4a 5.80.6a,b 5.10.5a 4.60.3
Data represent meanSEM. Abbreviations are: normo, normalbuminuric; micro, microalbuminuric diabetes; overt, overtproteinuric diabetes; and LDL, low-
density lipoprotein.
Significance (P  0.0033) was determined by ANOVA. avs. control; bvs. normo; cvs. micro; dvs. overt; evs. diabetic hemodialysis; fvs. nondiabetic hemodialysis
Tokyo, Japan), as described previously [17]. Plasma apo- by Pearson’s simple linear regression analysis. Statistical
significance was accepted at P  0.05.proteins were determined by the conventional immuno-
Multiple linear regression analysis was performed toturbidometric assay. VLDL (density 1.006 g/mL) was
examine whether the associations between VLDL apo CIseparated from plasma by ultracentrifugation (Hitachi
and kidney function, plasma lipids, or VLDL componentsCP-65G; Hitachi Co., Ltd., Tokyo, Japan) with an RP
were independent of VLDL apo CIII.55T-708 rotor (Hitachi Co., Ltd.). Then, the apo B level
in VLDL was measured by an enzyme-linked immuno-
sorbent assay (ELISA) as described by Young et al [18] RESULTS
using monoclonal antibody to apo B (MABO 12, Chemi-
As shown in Table 1, age and gender were comparablecon International, Inc., Temecula, CA, USA). The ELISA
between the controls, the diabetic patients with normo-methods for apo CI and CIII in VLDL were established
albuminuria, microalbuminuria, overt proteinuria, or CRFin our laboratory. Briefly, antihuman apo C1 or CIII mono-
treated with hemodialysis and the nondiabetic hemodial-clonal antibodies (Biogenesis, Inc., Kingston, NH, USA)
ysis patients. Body mass index (BMI) was comparablein carbonate buffer were coated on plates. Samples or
between these groups, except except that nondiabeticstandard apoproteins were added to each well and incu-
hemodialysis patients had lower BMI than the others.
bated. Goat antihuman apo CI or CIII antibodies (Ig G)
Serum creatinine levels were significantly higher and al-
(Chemicon International, Inc.) were added and incu- bumin was lower in the diabetic patients with protein-
bated. After washing, alkaliphosphatase-labeled antigoat uria, while these levels in normoalbuminuric and mi-
IgG (Chemicon International, Inc.) were added and incu- croalbuminuric diabetic patients were comparable to
bated. After washing, enzyme substrate solution (p-nitro- controls. Both diabetic and nondiabetic hemodialysis pa-
phenylphosphate in 1 mol/L diethanolamine, pH 9.8) was tients had marked high serum creatinine and slightly low
added. The resulting color was measured at 405 nm with albumin concentrations, and these values were similar in
an automated microplate reader (EL  808; Bio-Tek, diabetic and nondiabetic hemodialysis patients. Fasting
Winooski, VT, USA). The intra-assay coefficient of vari- plasma glucose and hemoglobin A1c levels were higher
ation was 6% to 9% for measurement of these apoprot- in the diabetic group than in nondiabetic subjects, but
eins by ELISA. Each ELISA was sensitive and suitable hemoglobin A1c levels were not elevated in diabetic he-
for detecting small amounts of apoproteins in isolated modialysis patients. Hemoglobin A1c values were compa-
lipoprotein fractions, but plasma apo CI and CIII levels rable among normoalbuminuric, microalbuminuric, and
could not be measured probably because a component of overt proteinuric diabetic groups.
plasma interfered with the assay. Therefore, the plasma Table 2 shows the levels of plasma lipids and apopro-
apo CI concentration was not determined in this study teins in each group. Plasma triglyceride levels increased
and plasma apo CIII was measured by the conventional with increasing severity of diabetic nephropathy, but the
immunoturbidimetry method. level was lower in diabetic hemodialysis patients than
Differences between groups were assessed by analysis in diabetic patients with proteinuria. Total and LDL
of variance (ANOVA) and then a post-hoc test was per- cholesterol levels were slightly higher in diabetic patients
formed using Bonferroni/Dunn–type multiple compari- than in controls and were the highest in the diabetic
son. Statistical significance was set at P 0.0033. Correla- patients with overt proteinuria, but these levels declined
significantly in diabetic hemodialysis patients. Nondia-tion coefficients between two variables were calculated
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Table 3. Very low-density lipoprotein (VLDL) concentration and composition
Type 2 diabetes
Nondiabetic Nondiabetic
control Normo Micro Overt Hemodialysis hemodialysis
Number 42 39 15 17 17 29
VLDL TG mg/100 mL 434 527a 6312a,f 1026a,b,c,f 809a,f 395
VLDL Chol mg/100 mL 121 162a 213 324a,b,c,f 233a,f 132
VLDL Apo B mg/100 mL 131 121 183 263a,b,f 253a,f 152
VLDL Apo CI mg/100 mL 1.50.2 2.00.4 2.60.7 4.60.9a,b,e 3.90.3a,b 2.50.2a
VLDL Apo CIII mg/100 mL 2.90.2 3.00.4 3.00.4 4.60.6 7.70.7a,b,c,d 7.70.8a,b,c,d
Apo CI/Apo B w/w 0.120.02 0.140.02 0.120.03 0.180.03 0.180.02 0.180.03
Apo CIII/Apo B w/w 0.300.04 0.310.05 0.230.05 0.210.04 0.360.05 0.510.11a,b,c,d
Data represent meanSEM. Abbreviations are: normo, normalbuminuric; micro, microalbuminuric diabetes; overt, overtproteinuric diabetes; TG, triglyceride;
Chol, cholesterol; apo, apoprotein.
Significance (P  0.0033) was determined by ANOVA. avs. control; bvs. normo; cvs. micro; dvs. overt; evs. diabetic hemodialysis; fvs. nondiabetic hemodialysis
betic hemodialysis patients had similar plasma triglycer- VLDL apo CIII were markedly increased in nondiabetic
ide levels, but lower total and LDL cholesterol levels, hemodialysis patients and were similar to those in dia-
when compared with diabetic groups. HDL cholesterol betic hemodialysis patients. The apo CI/apo B ratio, indi-
was lower in all diabetic groups and nondiabetic hemodi- cating the apo CI content of VLDL particles, was similar
alysis patients than in the controls, and the diabetic he- among all groups. The apo CIII/apo B ratio, indicating
modialysis group had the lowest HDL cholesterol level. the apo CIII content of VLDL particles, was markedly
Similarly, apo AI levels were substantially lower in dia- increased in nondiabetic hemodialysis patients, but apo
betic hemodialysis patients than in the other groups. CIII enrichment was not clearly observed in patients
Plasma apo B levels were significantly higher in diabetic with diabetic nephropathy.
patients than in controls, and diabetic patients with
Table 4 shows the correlations of VLDL apo CI orovertproteinuria had the highest level, while apo B was
VLDL apo CIII with various plasma parameters in allnot elevated in diabetic or nondiabetic hemodialysis pa-
subjects. VLDL apo CI was significantly related to uri-tients. Plasma apo CII, apo CIII, and apo E levels all
nary albumin excretion, but not to serum creatinine orincreased significantly with increasing severity of diabetic
albumin, whereas VLDL apo CIII was significantly re-nephropathy. The nondiabetic hemodialysis group had
lated to serum creatinine or albumin, but not to urinarya higher plasma apo CIII level, but their apo CII and
albumin excretion. Neither VLDL apo CI nor VLDLapo E levels were not elevated when compared with the
apo CIII was correlated with glycemic control. VLDLcontrols.
apo CI levels were closely associated with plasma triglyc-Table 3 shows the VLDL level and its apoprotein
eride level and with apo B, CII, CIII, and E levels. VLDLcomponents in each group. Like plasma triglyceride lev-
els, VLDL triglyceride levels increased in diabetic pa- apo CI levels showed also a significant inverse correla-
tients with increasing severity of diabetic nephropathy, tion with HDL cholesterol. VLDL apo CIII levels were
but the level in diabetic hemodialysis patients was lower closely associated with plasma triglyceride and apo B,
than in diabetic patients with overt proteinuria. VLDL CII, and CIII levels, but the correlation coefficients were
cholesterol concentrations showed a similar profile to lower than those for VLDL apo CI, except in the case
VLDL triglyceride. VLDL apo B levels showed signifi- of plasma apo CIII. VLDL apo CIII levels also showed
cant increase in diabetic patients with overt proteinuria significantly an inverse correlation with HDL choles-
and hemodialysis. In contrast, nondiabetic hemodialysis terol.
patients had comparable VLDL triglyceride, cholesterol, In an attempt to evaluate whether the correlation of
and apo B levels to those in controls. VLDL apo CI levels VLDL apo CI with various parameters was independent
were significantly elevated in the diabetic patients with
of the influence of VLDL apo CIII, multiple linear re-overt proteinuria and diabetic hemodialysis patients, be-
gression analysis was performed using VLDL apo CI anding 3.1- and 2.6-fold higher than in controls, respectively.
VLDL apo CIII as the independent variables (Table 5).VLDL apo CI levels were also slightly elevated in nondi-
The VLDL apo CI level was significantly correlated withabetic hemodialysis patients, but this increase was not
urinary albumin excretion and with the plasma levels ofsignificant. VLDL apo CIII levels were not elevated in
lipids and apoproteins. The VLDL apo CI level wasdiabetic patients with normoalbuminuria, microalbumin-
also significantly (P  0.0001) correlated with VLDLuria, or overt proteinuria, but were significantly elevated
triglyceride, VLDL cholesterol, and VLDL apo B inde-in diabetic hemodialysis patients (being 2.7-fold higher
than in controls). Unlike VLDL apo CI, the levels of pendently of VLDL apo CIII.
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Table 4. Correlation coefficients of very low-density lipoprotein (VLDL) apolipoprotein (apo) CI and VLDL apo CIII with various plasma
parameters in total subjects
VLDL apo CI Significance VLDL apo CIII Significance
r P r P
Creatinine 0.117 NS 0.172 0.05
Albumin 0.091 NS 0.172 0.05
Albumin/creatinine 0.337 0.0005 0.149 NS
Hemoglobin A1c 0.192 NS 0.137 NS
Plasma glucose 0.156 NS 0.152 NS
Plasma triglyceride 0.731 0.0001 0.432 0.0001
Plasma total cholesterol 0.225 0.01 0.049 NS
LDL cholesterol 0.100 NS 0.089 NS
HDL cholesterol 0.309 0.0001 0.227 0.005
Plasma apo AI 0.218 0.01 0.160 NS
Plasma apo B 0.370 0.0001 0.192 0.02
Plasma apo CII 0.595 0.0001 0.389 0.0001
Plasma apo CIII 0.516 0.0001 0.644 0.0001
Plasma apo E 0.411 0.0001 0.245 0.005
VLDL triglyceride 0.750 0.0001 0.391 0.0001
VLDL cholesterol 0.734 0.0001 0.365 0.0001
VLDL apo B 0.599 0.0001 0.436 0.0001
VLDL apo CI — 0.296 0.0002
VLDL apo CIII 0.296 0.0002
Table 5. Multiple regression analysis of very low-density (VLD) apolipoprotein (apo) CI or very low-density lipoprotein (VLDL) apo CIII
as an independent variable with various dependent variables in total subjects
Independent variables
VLDL apo CI VLDL apo CIII
Standardized Standardized
Dependent variables coefficient t value P value coefficient t value P value R2
Creatinine 0.057 0.807 NS 0.588 8.369 0.0001 0.329
Albumin 0.044 0.486 NS 0.154 1.721 NS 0.030
Albumin/creatinine 0.332 2.704 0.008 0.012 0.099 NS 0.113
Plasma triglyceride 0.665 11.976 0.0001 0.223 4.013 0.0001 0.580
Plasma total cholesterol 0.263 3.171 0.002 0.128 1.510 NS 0.066
High density lipoprotein cholesterol 0.273 3.3376 0.001 0.122 1.510 NS 0.109
Plasma apo AI 0.191 2.171 0.032 0.084 0.950 NS 0.055
Plasma apo B 0.348 4.153 0.0001 0.067 0.796 NS 0.141
Plasma apo CII 0.525 6.253 0.0001 0.214 2.540 0.013 0.395
Plasma apo CIII 0.337 4.559 0.0001 0.542 7.330 0.0001 0.528
Plasma apo E 0.375 4.574 0.0001 0.114 1.395 NS 0.181
VLDL triglyceride 0.699 12.73 0.0001 0.173 3.153 0.002 0.590
VLDL cholesterol 0.691 12.118 0.0001 0.201 2.550 0.012 0.558
VLDL apo B 0.519 7.906 0.0001 0.271 4.130 0.0001 0.426
NS  P  0.05.
DISCUSSION recently reported that the prospective CARE study
showed that the VLDL apo B level is an independentThe physiologic role and clinical significance of apo
and powerful predictor of recurrent coronary events,CI are largely unknown. However, Bjorkegren et al [19]
being superior to plasma triglyceride or LDL cholesterolhave recently reported that the apo CI content of VLDL
levels. We recently reported that VLDL triglyceride,particles shows a significant increase after fat loading in
cholesterol, and apo B levels were all increased in CHDpatients with CHD. We have also found that high levels
patients, with the increase of VLDL apo B being moreof VLDL apo CI are significantly associated with CHD
prominent than that of VLDL lipids [ 23]. These results[11]. The available evidence therefore suggests that apo
suggest that the number of circulating VLDL particlesCI plays an important role in increasing the atherogenic
may be strongly associated with the progression of CHD.potential of VLDL. Steiner et al [20] and Tkac et al
In this study, we found that VLDL apo B was signifi-[21] have demonstrated that VLDL apo B levels are
cantly correlated with VLDL apo CI. Experimental stud-associated with the angiographic severity of CHD in both
diabetic and nondiabetic individuals. Sacks et al [22] ies have suggested that apo CI plays an important role
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in the clearance of VLDL through inhibiting uptake by nondiabetic hemodialysis patients were normotriglyceri-
the liver [12–14]. Therefore, it is reasonable to assume demic. Accordingly, these patients may not have all of
that an increase of apo CI delays particle clearance, the typical lipid abnormalities of CRF patients. Further
which results in an increase of VLDL particles in the studies will be required to elucidate the mechanism of
circulation. lipoprotein abnormalities in nondiabetic hemodialysis
Gene targeting mouse studies [13] have demonstrated patients with hypertriglyceridemia. Sacks et al [22] found
that apo CI inhibits VLDL particle uptake but does not that the apo CIII concentration of the VLDL  LDL
interfere with glycosaminoglycan binding or triglyceride fraction was an independent coronary risk factor in the
hydrolysis of VLDL, while apo CIII predominantly inter- CARE study. Thus, we should also pay attention to an
feres with glycosaminoglycan binding or lipolysis of increase of VLDL apo CIII as a strong risk factor for
VLDL. It has also been reported that apo CIII inhibits CHD in patients with CRF regardless of the presence
VLDL removal by suppressing its binding to the LDL of diabetes. In this study, we only focused on VLDL
receptor, while apo CI predominantly inhibits LDL re- abnormalities associated with apo CI and CIII, but IDL
ceptor-related protein (LRP) or VLDL receptors [24]. abnormalities represent another important risk factor
Cross breeding of apo CI transgenic mice with LDL for renal disease that we have not assessed, and apo CI
receptor knockout mice leads to severe hypertriglyceri- or apo CIII may also play a role in such abnormalities.
demia [14], suggesting that apo CI impairs the catabolism Therefore, further studies will be required to elucidate
of VLDL via LDL receptor-independent pathways. If the role of these proteins in dyslipidemia associated with
VLDL is promptly taken up by LRP or the VLDL recep- diabetic nephropathy or CRF.
tor in certain circumstances, apo CI may be a crucial
factor for VLDL removal. There is a possibility that
CONCLUSIONmetabolic derangement in diabetic nephropathy might
lead to changes of apo CI. Our results suggest that an increase of VLDL apo CIII
Attman et al [5, 25] extensively examined the apopro- is a prominent feature of dyslipidemia in CRF patients,
tein concentrations in lipoprotein fractions from diabetic regardless of whether they are diabetic or nondiabetic,
and nondiabetic patients with CRF not on hemodialysis, whereas an increase of VLDL CI is more specific to
and reported that VLDL apo CIII was significantly in- diabetic nephropathy and is closely associated with an
creased in both diabetic and nondiabetic patients. Simi- increase of VLDL particle numbers, a new risk factor
larly, we found that VLDL apo III levels were elevated for CHD.
in both diabetic and nondiabetic hemodialysis patients
to about the same extent. These studies suggest that an ACKNOWLEDGMENT
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